GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Iconovo AB (OSTO:ICO) » Definitions » EV-to-EBITDA

Iconovo AB (OSTO:ICO) EV-to-EBITDA : -0.95 (As of Jun. 27, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Iconovo AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Iconovo AB's enterprise value is kr29.74 Mil. Iconovo AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was kr-31.43 Mil. Therefore, Iconovo AB's EV-to-EBITDA for today is -0.95.

The historical rank and industry rank for Iconovo AB's EV-to-EBITDA or its related term are showing as below:

OSTO:ICO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -3077.96   Med: -20.16   Max: 134.59
Current: -0.94

During the past 9 years, the highest EV-to-EBITDA of Iconovo AB was 134.59. The lowest was -3077.96. And the median was -20.16.

OSTO:ICO's EV-to-EBITDA is ranked worse than
100% of 496 companies
in the Medical Devices & Instruments industry
Industry Median: 15.47 vs OSTO:ICO: -0.94

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-06-27), Iconovo AB's stock price is kr1.985. Iconovo AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was kr-2.191. Therefore, Iconovo AB's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Iconovo AB EV-to-EBITDA Historical Data

The historical data trend for Iconovo AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iconovo AB EV-to-EBITDA Chart

Iconovo AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only -25.15 -28.17 -11.25 -4.55 -2.39

Iconovo AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.26 -4.54 -2.67 -2.39 -1.58

Competitive Comparison of Iconovo AB's EV-to-EBITDA

For the Medical Devices subindustry, Iconovo AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Iconovo AB's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Iconovo AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Iconovo AB's EV-to-EBITDA falls into.


;
;

Iconovo AB EV-to-EBITDA Calculation

Iconovo AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=29.743/-31.43
=-0.95

Iconovo AB's current Enterprise Value is kr29.74 Mil.
Iconovo AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-31.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Iconovo AB  (OSTO:ICO) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Iconovo AB's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.985/-2.191
=At Loss

Iconovo AB's share price for today is kr1.985.
Iconovo AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-2.191.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Iconovo AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Iconovo AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Iconovo AB Business Description

Traded in Other Exchanges
N/A
Address
Ideongatan 3 A-B, Delta 6, Lund, SWE, SE-223 62
Iconovo AB develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The project is a generic version of the asthma and COPD product Symbicort.

Iconovo AB Headlines

No Headlines